EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab

Yan Wang, Laura H Bukkems, Johan G C van Hasselt, Marie-Rose Crombag, Daphne Dumoulin, Jeroen J M A Hendrikx, Willemijn Theelen, Tom van der Hulle, Ellen Kapiteijn, Juliëtte Zwaveling, Annemarie Becker, Jeroen Hiltermann und 9 weitere

European Journal of Cancer · 2026-07 · 243 · 116829

DOI: 10.1016/j.ejca.2026.116829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-07. Verfasst von Yan Wang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, the Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Drug Costs, Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDrug CostsAntineoplastic Agents, ImmunologicalNeoplasmsHumansCost SavingsInjections, SubcutaneousCost-Benefit AnalysisDrug Administration Schedule

Stichwörter der Autor:innen

Cost-effectivenessModeling and simulationPembrolizumabPharmacokinetics

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, the Netherlands.
  • Leiden Academic of Drug research, Leiden, the Netherlands.
  • Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Förderung

  • China Scholarship Council

Zitieren

APA

Wang, Y., Bukkems, L. H., van Hasselt, J. G. C., Crombag, M. R., Dumoulin, D., Hendrikx, J. J. M. A., Theelen, W., van der Hulle, T., Kapiteijn, E., Zwaveling, J., Becker, A., Hiltermann, J., Hendriks, L. E. L., van Geel, R. M. J. M., van Geffen, W. H., van den Heuvel, M., Oude Munnink, T. H., Smit, E. F., Guchelaar, H. J., …, & Ter Heine, R. (2026). Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab. European Journal of Cancer, 243, 116829. https://doi.org/10.1016/j.ejca.2026.116829

Vancouver

Wang Y, Bukkems LH, van Hasselt JGC, Crombag MR, Dumoulin D, Hendrikx JJMA, et al. Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab. European Journal of Cancer. 2026;243:116829. doi:10.1016/j.ejca.2026.116829

BibTeX
@article{Wang2026,
  author = {Wang, Yan and Bukkems, Laura H and van Hasselt, Johan G C and Crombag, Marie-Rose and Dumoulin, Daphne and Hendrikx, Jeroen J M A and Theelen, Willemijn and van der Hulle, Tom and Kapiteijn, Ellen and Zwaveling, Juliëtte and Becker, Annemarie and Hiltermann, Jeroen and Hendriks, Lizza E L and van Geel, Robin M J M and van Geffen, Wouter H and van den Heuvel, Michel and Oude Munnink, Thijs H and Smit, Egbert F and Guchelaar, Henk-Jan and Moes, Dirk Jan A R and Ter Heine, Rob},
  title = {Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {243},
  pages = {116829},
  doi = {10.1016/j.ejca.2026.116829}
}
Kostenlos starten →